[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"TCI Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,68,91,109,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100400642","the-evaluation-of-orange-peel-fermentation-on-body-fat-lowering-efficacy-in-adults-100400642",false,"NCT04496895","The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults","Inclusion Criteria:\n\n1. Adults between the ages of 20 and 65 who are willing to sign the consent form of the subject.\n2. For those with BMI ≥ 24 or fatty liver, male body fat ≥ 25%, female body fat ≥ 30%.\n3. Those who are not pregnant and are willing to cooperate with contraception during the trial period.\n4. No history of cardiovascular disease, history of organ transplantation, history of epilepsy or convulsions, liver and kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history).\n\nExclusion Criteria:\n\n1. Pregnant women, people with a history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history).\n2. No person who has received major surgery or bariatric surgery (according to medical history).\n3. I have used drugs that affect body fat, waist circumference or significantly increase weight, such as systemic corticosteroids, tricyclic antidepressants, atypical psychiatric drugs, and mood stability in the current or 3 months before participating in the screening Drugs (according to medical history).",true,"ALL","20 Years","65 Years",{"count":20,"type":21},124,"ESTIMATED","INTERVENTIONAL",[24],"NA","To assess whether orange peel fermentation has the effect of reducing body fat in adults",[27,28],"Overweight","Fatty Liver Disease","RECRUITING","2026-05-26",{"date":32,"type":33},"2026-05-29","ACTUAL",{"date":35,"type":33},"2022-11-12",{"date":37,"type":21},"2026-11-30",{"name":39,"class":40},"TCI Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100639832","effects-of-oral-collagen-drinks-on-human-skin-100639832","NCT07605871","Effects of Oral Collagen Drinks on Human Skin","Inclusion Criteria:\n\n* Healthy Chinese subjects aged 18 to 60 years, both male and female.\n* Wrinkle Severity: Crow's feet graded 2-4; under-eye fine lines graded 2-5; nasolabial folds graded 1-3.\n* Presence of facial skin laxity and sagging.\n* Ability to undergo skin examinations and pre-treatment in the designated test areas.\n* Ability to understand the trial process, participate voluntarily, and sign a written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or those planning to become pregnant in the near future.\n* Highly sensitive constitution, history of allergic diseases, or history of allergies to cosmetics.\n* Presence of skin diseases (e.g., psoriasis, eczema, atopic dermatitis, severe acne) or other chronic systemic diseases.\n* Skin conditions in the test area such as birthmarks, hyperpigmentation, inflammation, scars, nevi (moles), or hypertrichosis (excessive hair).\n* Use of anti-inflammatory drugs (e.g., oral or topical corticosteroids) within the past month.\n* Use of cosmetics or other products with similar efficacy within the past 2 weeks.\n* Participation in other human clinical trials for cosmetics within the past month.\n* Any other conditions deemed unsuitable for participation based on clinical assessment.","18 Years","60 Years",{"count":51,"type":21},99,[24],"The objective of this study is to evaluate the effect of oral collagen drink and MAXI collagen drink on human skin condition improvement.",[55,56],"Skin Condition","Collagen Synthesis",[58,59,60],"MAXI Collagen","Hydrolyzed collagen","Oral Collagen","2026-05-18",{"date":30,"type":33},{"date":64,"type":33},"2026-05-12",{"date":66,"type":21},"2026-06-30",{"name":39,"class":40},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100622099","efficacy-evaluation-study-of-vitamin-c-and-glutathione-liquid-sachet-100622099","NCT07379216","Efficacy Evaluation Study of Vitamin C and Glutathione Liquid Sachet","Inclusion Criteria:\n\n* Healthy male or female adults, aged 18-65 years old;\n* Commitment not to use products having activity comparable with that of the product to be tested during the study period;\n* Free of any dermatological or systemic disorder that would interfere with results.\n\nExclusion Criteria:\n\n* Subject with obvious skin surface damage;\n* Subject who had oral or topical medication which may affect skin condition within 1 month;\n* Individuals with known allergies to cosmetics, medications, or foods (especially those allergic to legumes\u002Fsoy);\n* Pregnant or breastfeeding individuals;\n* Received facial laser therapy, chemical peeling in the past 2 months.\n* Individuals unwilling to allow publication or public disclosure of photographs taken as part of the study results",{"count":75,"type":21},30,[24],"The objective of this study is to evaluate the effect of liquid vitamin C and glutathione supplements on human skin condition improvement and anti-oxidation.",[55,79],"Anti-Oxidative Stress",[81,82],"Vitamin C supplement","Glutathione supplement","2026-02-02",{"date":85,"type":33},"2026-02-04",{"date":87,"type":33},"2026-01-24",{"date":89,"type":21},"2026-06-01",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":41},"100606211","the-effect-of-avnace-ezze-on-sleep-improvement-100606211","NCT07172607","The Effect of Avnace eZZe on Sleep Improvement","Inclusion Criteria:\n\n* Male or female age 18 years or older;\n* Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) criteria for Insomnia Disorder;\n* Regular bedtime, between 21:00 and 01:00 and regular wake time;\n* Insomnia Severity Index (ISI) score ≥15;\n* All medications or interventions for insomnia, mental or physical disorders must have been stable for at least four weeks prior to screening, and participants had to be willing to maintain a stable regimen throughout the study;\n* No consumption of sleep or stress-related supplements for at least four weeks prior to screening;\n* Willing and able to comply with all aspects of the protocol.\n\nExclusion Criteria:\n\n* A current diagnosis of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorder;\n* Depressive symptoms at screening were considered significantly severe with a PHQ-9 score \\> 14\n* Anxiety symptoms at screening were considered significantly severe with a GAD-7 score \\> 15;\n* Females who are breastfeeding or pregnant;\n* Females of childbearing potential who are not practicing acceptable pregnancy prevention methods (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically.);\n* Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or habitually consumes caffeine-containing beverages after 18:00 and is unwilling to forego caffeine after 18:00 for the duration of his\u002Fher participation in the study;\n* History of drug or alcohol dependency or abuse within approximately the previous 2 years;\n* Current evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal, neurological, or psychiatric disease or malignancy or chronic pain that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments;\n* Scheduled for major surgery during the study;\n* Participants known to be allergic to any components of the product.",{"count":98,"type":21},75,[24],"This study aims to examine the effectiveness of Avance eZZe drink with liposomal technology in improving sleep quality. Participants will be randomly assigned to either the placebo group, Avance eZZe drink group, and Avance eZZe drink without liposomal group, with 25 participants in each group. On the day of the experiment (day 0), participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them 1 hour before sleep daily for 28 days. Follow-up assessments will be conducted in the day-1, day-14 and day-28, participants are required to fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions.",[102,103],"Sleep Disorder (Disorder)","Anxiety Depression Disorder",{"date":85,"type":33},{"date":106,"type":33},"2025-09-09",{"date":66,"type":21},{"name":39,"class":40},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100603349","the-efficacy-evaluation-of-tci604-probiotic-on-intestinal-function-improvement-100603349","NCT07135362","The Efficacy Evaluation of TCI604 Probiotic on Intestinal Function Improvement","The Efficacy Evaluation of Bifidobacterium Animalis Subsp. Lactis TCI604 Probiotic on Intestinal Function Improvement","Inclusion Criteria:\n\n* Male or non-pregnant female subjects aged 18 to 65 who are willing to sign the informed consent form;\n* Diagnosed with functional constipation as assessed by a physician;\n* Non-pregnant females who agree to use physical contraceptive methods during the study period (e.g., condoms, intrauterine devices);\n* No history of organ transplantation, epilepsy or seizures, liver or kidney disease, malignancy, psychiatric disorders, alcohol or drug abuse, or other major organic diseases (as determined by medical history).\n\nExclusion Criteria:\n\n* Use of probiotics, gastrointestinal health supplements, medications, or antibiotics within 30 days prior to the study;\n* Presence of chronic gastrointestinal diseases (e.g., irritable bowel syndrome \\[IBS\\], inflammatory bowel disease \\[IBD\\], Crohn's disease, celiac disease, bowel control problems\u002Ffecal incontinence, pancreatitis, peptic ulcers, colorectal cancer, short bowel syndrome, ulcerative colitis);\n* History of gastrointestinal or major surgery;\n* Lactose intolerance;\n* Chronic diarrhea;\n* Pregnant or breastfeeding women;\n* Known allergy to any components of the study product.",{"count":117,"type":21},60,[24],"The objective of this study is to evaluate whether the TCI604 probiotics has the potential to enhance human gut function and alleviate constipation.",[121,122],"Constipation","Intestinal Functional Disorder",[124],"Bifidobacterium animalis subsp. lactis","2025-08-18",{"date":127,"type":33},"2025-08-22",{"date":129,"type":33},"2025-08-11",{"date":131,"type":21},"2026-07-31",{"name":39,"class":40},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100400168","the-efficacy-evaluation-of-buckwheat-husk-extract-on-cardiovascular-disease-risk-factors-100400168","NCT04490720","The Efficacy Evaluation of Buckwheat Husk Extract on Cardiovascular Disease Risk Factors","Inclusion Criteria:\n\n1. 20 to 65-year-old males or non-pregnant females who are willing to sign the subject's consent.\n2. The systolic blood pressure is 121-139 mmHg and the diastolic blood pressure is between 81-89 mmHg.\n3. Those who are not pregnant and are willing to cooperate with contraception during the trial period.\n4. No history of organ transplantation, epilepsy or convulsions, liver or kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history).\n\nExclusion Criteria:\n\n1. Pregnant women.\n2. People with a history of organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history).\n3. No person has undergone major surgery.",{"count":117,"type":21},[24],"To assess the efficacy evaluation of buckwheat husk extract on cardiovascular disease risk factors",[143],"Cardiovascular Diseases","2025-01-08",{"date":146,"type":33},"2025-01-09",{"date":148,"type":33},"2021-11-24",{"date":150,"type":21},"2026-02-28",{"name":39,"class":40},""]